The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities[2]. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Vasonatrin peptide (VNP) 是心房钠尿肽 (ANP) 和C型利尿钠肽 (CNP) 的嵌合体,具有高效的静脉扩张和利钠活性。- 高纯度,全球文献引用。Vasonatrin Peptide VNP | Others | Inhibitor | inhibitor | inhibitVasonatrin peptide (VNP) 是心房钠尿肽 (ANP) 和C型利尿钠肽 (CNP) 的嵌合体,具有高效的静脉扩张和利钠活性。- 高纯度,全球文献引用。Vasonatrin Peptide VNP
本文链接: http://vnpchemical.immuno-online.com/view-730245.html